Key result
DPP-4 inhibitors lower HbA1c by ~0.5% versus placebo in T2D with moderate-to-severe renal impairment.
Why the study?
The efficacy and safety of DPP-4 inhibitors in T2DM patients with moderate to severe renal impairment were not well established.
Do DPP-4 inhibitors reduce HbA1c and improve safety outcomes in T2DM patients with moderate to severe renal impairment?
Meta-Analysis (n=1,915)
Do DPP-4 inhibitors reduce HbA1c and improve safety outcomes in T2DM patients with moderate to severe renal impairment?
DPP-4 inhibitors effectively lower HbA1c without increasing the risk of hypoglycemia or adverse events in patients with T2DM and moderate to severe renal impairment.
Answers are grounded in this paper and cite their sources.
Supports DPP-4 inhibitor use for glycemic control in T2DM with renal impairment; extends RCT evidence but leaves open due to low-quality data.
OBJECTIVE: To perform a systematic review and meta-analysis regarding the efficacy and safety of dipeptidyl peptidase-4 (DDP-4) inhibitors ("gliptins") for the treatment of type 2 diabetes mellitus (T2DM) patients with moderate to severe renal impairment. METHODS: All available randomized-controlled trials (RCTs) that assessed the efficacy and safety of DDP-4 inhibitors compared with placebo, no treatment, or active drugs were identified using PubMed, EMBASE, Cochrane CENTRAL, conference abstracts, clinical trials.gov, pharmaceutical company websites, the FDA, and the EMA (up to June 2014). Two independent reviewers extracted the data, and a random-effects model was applied to estimate summary effects. RESULTS: Thirteen reports of ten studies with a total of 1,915 participants were included in the final analysis. Compared with placebo or no treatment, DPP-4 inhibitors reduced HbA1c significantly (-0.52%, 95%CI -0.64 to -0.39) and had no increased risk of hypoglycemia (RR 1.10, 95%CI 0.92 to 1.32) or weight gain. In contrast to glipizide monotherapy, DPP-4 inhibitors showed no difference in HbA1c lowering effect (-0.08%, 95% CI -0.40 to 0.25) but had a lower incidence of hypoglycemia (RR 0.40, 95%CI 0.23 to 0.69). Furthermore, DPP-4 inhibitors were well-tolerated, without any additional mortality and adverse events. However, the quality of evidence was mostly as low, as assessed using the GRADE system for each outcome. CONCLUSIONS: DPP-4 inhibitors are effective at lowering HbA1c in T2DM patients with moderate to severe renal impairment. DPP-4 inhibitors also have a potential advantage in lowering the risk of adverse events. Regarding the low quality of the evidence according to GRADE, additional well-designed randomized trials that focus on the safety and efficacy of DPP-4 inhibitors in various CKD stages are needed urgently.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2014) conducted a meta-analysis in Type 2 diabetes mellitus with moderate to severe renal impairment (n=1,915). Dipeptidyl peptidase-4 (DPP-4) inhibitors vs. Placebo or no treatment was evaluated on Mean change in HbA1c from baseline (MD -0.52, 95% CI -0.64 to -0.39, p=<0.00001). Dipeptidyl peptidase-4 inhibitors reduced HbA1c by a mean difference of 0.52% compared to placebo or no treatment in patients with type 2 diabetes and moderate to severe renal impairment.
Synapse has enriched 10 related papers. Consider them for comparative context: